AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00522106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Treatment according to the Dutch physiotherapy guideline for patients with osteoarthritis of hip and/or knee. This guideline consists of general recommendations, emphasizing provision of information and advice, exercise therapy, and encouragement of a positive coping with the complaints. The treatment consisted of a maximum of 18 sessions within a period of 12 weeks. The treatment could be discontinued within the 12 week period if, according to the physiotherapists, all treatment goals were achieved.
Study NCT03596723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPI-121 1%
Description: eye drops
Study NCT03596723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate
Description: eye drops
Study NCT01098500 — intervention group
Intervention type: DRUG
Intervention: Tyrosine kinase inhibitors
Description: Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
Study NCT04228146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Immediate access to the self-help CBT-I treatment, content of which is based on the translated Chinese version of a well-established CBT-I treatment manual entitled Insomnia: A Clinician's Guide to Assessment and Treatment. CBT-I aims at changing dysfunctional cognitive beliefs and maladaptive behaviors that contribute to the maintenance of insomnia. The self-help CBT-I treatment is delivered in Chinese language in six consecutive weekly modules via a smartphone application known as proACT-S. Duration of each module is around 45 to 60 minutes.
Study NCT04228146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Delay access to the self-help CBT-I treatment.
Study NCT02198716 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Coronary Intervention using drug eluting stents
Description: Percutaneous Coronary Intervention using drug eluting stents
Study NCT02198716 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Coronary Intervention using bare metal stents
Description: Percutaneous Coronary Intervention using bare metal stents
Study NCT04086576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcohoot
Description: Alcohoot branded smartphone-paired breathalyzer
Study NCT04086576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BACtrack Mobile Pro
Description: BACtrack Mobile Pro branded smartphone-paired breathalyzer
Study NCT04086576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRIVESAFE Evoc
Description: DRIVESAFE Evoc branded smartphone-paired breathalyzer
Study NCT04086576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BACtrack Vio
Description: BACtrack Vio branded smartphone-paired breathalyzer
Study NCT04086576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drinkmate
Description: Drinkmate branded smartphone-paired breathalyzer
Study NCT04086576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floome
Description: Floome branded smartphone-paired breathalyzer
Study NCT04086576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intoxilyzer 240
Description: Intoxilyzer 240 police grade breathalyzer
Study NCT04043962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT (Web-MAP)
Description: see arm description
Study NCT00377780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non pegylated liposomal doxorubicin, trastuzumab, docetaxel
Description: max. 6 courses
Study NCT02125448 — intervention group
Intervention type: DEVICE
Intervention: MRI and PET-CT
Study NCT03482505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00004
Description: The INVSENSOR00004 will be placed on the subject's neck or chest to provide acoustic respiration rate.
Study NCT03280771 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hope Soap
Description: HOPE SOAP© is a colourful, translucent bar of soap with a toy embedded in its centre.
Study NCT03280771 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control group soap
Description: A colourful, translucent bar or soap with the toy alongside it
Study NCT01394874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLC
Description: Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Arms C, D and E used in combination
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Arms C, D and E used in combination
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Arms C and D used in combination
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: Arm C used alone
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Arms C and D used in combination
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Arm D used in combination
Study NCT05484440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological
Study NCT03922217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful My Way
Description: Mindful My Way (MMW) is a mobile application created for iOS, designed to delivered a form of mindfulness-based therapy to depressed older adults
Study NCT00729157 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Correlative studies
Study NCT00729157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00729157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00729157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Correlative studies
Study NCT00729157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib Tablets.
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib Tablets.
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV injection.
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine IV injection.
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Tablets.
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone Tablets.
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine IV infusion.
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine IV infusion.
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate IV infusion.
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate IV infusion.
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Arm D used in combination
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Arm F used in combination
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone Tablets.
Study NCT03589326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone Tablets.
Study NCT01177293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine - reference
Description: Amlodipine capsule, 10 mg, single dose, with water
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Arm F used in combination
Study NCT03017326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Arm used in combination
Study NCT02020239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT00746096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKH-01
Description: ethinyl estradiol 0.035mg and norethisterone 1mg
Study NCT00746096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
Study NCT02378740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion
Study NCT02378740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion
Study NCT02980926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
Study NCT02980926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
Study NCT04387864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body Vibration Device
Description: Power Plate® (pro5TM; Power Plate North America, Inc., Northbrook, IL, USA)
Study NCT02597465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1507
Description: The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
Study NCT02597465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference1507
Description: Investigators choice including chemotherapy or supportive therapy
Study NCT03728608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Feeding tube dwell time of 48 hours
Description: Feeding tube dwell time of 48 hours for first 4 weeks of life.
Study NCT03728608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Feeding tube dwell time of 7 day
Description: Feeding tube dwell time of 7 days for first 4 weeks of life.
Study NCT00978484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy - Dynamic
Description: 10 weeks of Virtual Reality Exposure using full, immersive VR
Study NCT00978484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Exposure Therapy
Description: Exposure Therapy augmented with a still computer image
Study NCT01099514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: D1\~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
Study NCT03198286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive treatment summary and survivor care plan
Study NCT00953303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucocorticoid
Description: One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
Study NCT00953303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
Study NCT03056625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin A fortified rice
Description: Lactating women will receive fortified rice one meal per day on weekdays for a period of 14 weeks.
Study NCT03056625 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal rice
Description: Lactating women will receive normal rice one meal per day on weekdays for a period of 14 weeks.
Study NCT02613221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab + TAS-102
Description: panitumumab + TAS-102 combination therapy
Study NCT01465607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mujer Segura
Description: Brief (35-minute) counseling intervention using techniques from Motivational Interviewing and principles of social cognitive theory (SCT) and theory of reasoned action (TRA).
Study NCT01465607 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CENSIDA counseling program
Description: Didactic HIV and STI counseling involving some personal risk assessment and presenting appropriate information on methods of transmission and for avoiding or reducing the risk of infection. Based on a counseling manual disseminated by CENSIDA, Mexico's federal HIV-AIDS prevention agency.
Study NCT01194895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protective ventilation
Description: set tidal volume of 5ml/kg during one-lung ventilation
Study NCT01194895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional ventilation
Description: keep tidal volume at 8ml/kg during one-lung ventilation
Study NCT01177293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine ODT - test
Description: Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
Study NCT03343704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Description: Intravenous
Study NCT01868438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine-artesunate granules
Study NCT01868438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine-artesunate tablets
Study NCT03202940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib is an oral ALK inhibitor. The term ALK inhibitor means that alectinib targets the abnormal ALK protein that is causing lung cancer cells to grow
Study NCT03202940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib is an oral inhibitor of MEK, a signaling protein that can cause some types of lung cancer to grow
Study NCT01322789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Mesenchymal stem cell infusion
Description: Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart
Study NCT02848482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)
Study NCT02848482 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical debridement
Description: Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
Study NCT02848482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical debridement
Description: Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
Study NCT02848482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: 0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
Study NCT03489096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoballoon Ablation: PVI + substrate modification
Description: Standard pulmonary vein isolation using cryoballoon ablation, followed by left atrial fibrosis substrate modification using cryoballoon ablation
Study NCT03950609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT03950609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO
Study NCT04647799 — intervention group
Intervention type: DEVICE
Intervention: smartphone
Description: Samsung A 71
Study NCT02067884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced ultrasound imaging
Description: Undergo CEUS
Study NCT04444648 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: No intervention
Description: No intervention
Study NCT00626366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sinus CT Scan
Description: Subjects will undergo a Xoran miniCAT scan of their sinuses
Study NCT00626366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 240 Contrast Solution
Description: Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
Study NCT00626366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque 240 mg I/mL
Description: Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
Study NCT01191203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copper IUD
Description: Copper IUD (CuT360)
Study NCT01191203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo Medroxyprogesterone acetate
Description: DMPA 150 mg IM q 3 months
Study NCT04138836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-877
Description: BBT-877 oral capsule.
Study NCT02067884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shear wave elastography
Description: Undergo SWE
Study NCT02067884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity, (Lipid Microspheres) Intravenous Suspension
Description: Participant will receive contrast agent by intravenous administration
Study NCT04138836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral syrup.
Study NCT04138836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole oral capsule.
Study NCT04138836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole oral capsule.
Study NCT02067884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Shear Wave Elastography
Description: Equipment used for SWE
Study NCT00459342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally
Study NCT01677364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Arm - Induction of labour
Study NCT02546414 — intervention group
Intervention type: OTHER
Intervention: Platelet count/spleen diameter ratio
Description: Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
Study NCT04151784 — intervention group
Intervention type: OTHER
Intervention: Pulmonary Group
Description: Data collection will be obtained on the day an individual has an appointment at the pulmonary clinic. After patients meet with their pulmonary physicians, the physicians will inform them about the study and explain that participation is voluntary. If a patient agrees, the researcher will provide copies of the questionnaires and again clarify that participation is voluntary. The workflow of the clinic will not be interrupted while the researcher conducts the study, and he will only ask participants to fill out the questionnaires if they have enough time to participate.
Study NCT04151784 — intervention group
Intervention type: OTHER
Intervention: Healthy Control
Description: The second group will be recruited as a control group consisting of healthy adult participants through purposive convenience sampling at other collaborating UAB sites. The principal investigator will collect self-report responses through a questionnaire packet given to anyone willing to participate in the study
Study NCT00846443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Pemetrexed, Cisplatin and Radiotherapy
Description: pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
Study NCT00846443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Pemetrexed, Cisplatin and Radiotherapy
Description: pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions